A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer

Immunotherapy and immune checkpoint blocking antibodies such as anti-PD-1 are approved and significantly improve the survival of advanced non-small cell lung cancer (NSCLC) patients, but there has been little success in identifying biomarkers capable of separating the responders from non-responders...

Descripción completa

Detalles Bibliográficos
Autores principales: Jafarnejad, Mohammad, Gong, Chang, Gabrielson, Edward, Bartelink, Imke H., Vicini, Paolo, Wang, Bing, Narwal, Rajesh, Roskos, Lorin, Popel, Aleksander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591205/
https://www.ncbi.nlm.nih.gov/pubmed/31236847
http://dx.doi.org/10.1208/s12248-019-0350-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591205/
https://www.ncbi.nlm.nih.gov/pubmed/31236847
http://dx.doi.org/10.1208/s12248-019-0350-x

Ejemplares similares